2. Gene
  3. Cdk1 - cyclin-dependent kinase 1 Gene

Cdk1 - cyclin-dependent kinase 1 Gene

  • Gene
  • Protein
  • Agent
  • Ortholog
Mus musculus

Also known as Cdc2; Cdc2a; p34

Gene ID: 12534 | Gene type: protein coding

About Cdk1

Chromosome 10: 69,170,976-69,188,768 reverse strand.GRCm39:CM001003.3

This gene has 7 transcripts (splice variants), 246 orthologues, 25 paralogues and is associated with 8 phenotypes. Biased expression in liver E14 (RPKM 47.), placenta adult (RPKM 44.1) and 11 other tissues.

Summary

Enables HSP70 protein binding activity; chromatin binding activity; and cyclin-dependent protein serine/threonine kinase activity. Acts upstream of or within several processes, including mitotic G2 DNA damage checkpoint signaling; mitotic cell cycle phase transition; and protein phosphorylation. Colocalizes with mitochondrial matrix. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; respiratory system; and sensory organ. Human ortholog(s) of this gene implicated in breast cancer; cervical cancer; and urinary bladder Cancer. Orthologous to human CDK1 (cyclin dependent kinase 1). [provided by Alliance of Genome Resources, Apr 2022]

Cdk1 Products(1)

mRNA Protein Name
NM_007659.4 NP_031685.2 cyclin-dependent kinase 1
Gene Ontology
  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence Reference Source
enables Hsp70 protein binding IPI
IPI: Inferred from physical interaction
9247342 MGI
enables chromatin binding IDA
IDA: Inferred from direct assay
18625720 MGI
enables cyclin-dependent protein kinase activity IDA
IDA: Inferred from direct assay
27565725 MGI
enables cyclin-dependent protein serine/threonine kinase activity IDA
IDA: Inferred from direct assay
22405274 MGI
enables kinase activity IDA
IDA: Inferred from direct assay
12124778 MGI
enables protein binding IPI
IPI: Inferred from physical interaction
11687586 MGI
enables protein serine/threonine kinase activity IDA
IDA: Inferred from direct assay
29518391 MGI
Biological Process GO Annotation Evidence Reference Source
acts upstream of or within fibroblast proliferation IDA
IDA: Inferred from direct assay
18625720 MGI
acts upstream of or within mitotic G2 DNA damage checkpoint signaling IDA
IDA: Inferred from direct assay
12937170 MGI
acts upstream of or within mitotic cell cycle phase transition IMP
IMP: Inferred from mutant phenotype
18625720 MGI
acts upstream of or within protein phosphorylation IDA
IDA: Inferred from direct assay
12124778 MGI
Cellular Component GO Annotation Evidence Reference Source
part of cyclin A2-CDK1 complex IPI
IPI: Inferred from physical interaction
19592082 MGI
colocalizes with mitochondrial matrix IDA
IDA: Inferred from direct assay
24746669 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Cdk1 Protein Structure

STKc_CDK1_euk

STKc_CDK1_euk: cd07861 (2 - 286)

  • 0
  • 100
  • 200
  • 297 a.a.
Protein Preferred Names Protein Names

cyclin-dependent kinase 1

cell cycle p34 CDC2 kinase protein

cell division control protein 2 homolog

cell division cycle 2 homolog A

cell division cycle control protein 2a

cell division protein kinase 1

p34 protein kinase

Recombinant Cdk1 Proteins

Cat. No. Product Name Accession Purity
HY-P75669 CDK1 Protein, Mouse (sf9, His-GST) P11440 (M1-M297) ≥95%

Related Agents

Approval
Bioactive Molecules (4)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-16297A Abemaciclib Inhibitor 99.97% Yes
HY-10492 Dinaciclib Inhibitor 99.36% Yes
HY-16297 Abemaciclib methanesulfonate Inhibitor 99.95% Yes
HY-B0263 Thiabendazole Inhibitor 99.77% Unkown
Clinical Phase
Bioactive Molecules (27)
Cat. No. Product Name Effect
Purity Phase
HY-10580 GSK 3 Inhibitor IX Inhibitor 99.74% Phase 4
HY-112272 Lerociclib Inhibitor 98.35% Phase 3
HY-10005 Flavopiridol Inhibitor 99.73% Phase 2
HY-30237 (R)-Roscovitine Inhibitor 99.84% Phase 2
HY-103712A Samuraciclib hydrochloride Inhibitor 99.98% Phase 2
HY-50940 AT7519 Inhibitor 99.76% Phase 2
HY-10006 Flavopiridol Hydrochloride Inhibitor 99.73% Phase 2
HY-13914 Roniciclib Inhibitor 98.09% Phase 2
HY-10424 Milciclib Inhibitor 99.90% Phase 2
HY-112272A Lerociclib dihydrochloride Inhibitor 98.11% Phase 2
HY-103712B Samuraciclib hydrochloride dihydrate Inhibitor 99.08% Phase 2
HY-137432 Avotaciclib Inhibitor 99.72% Phase 2
HY-50943 AT7519 Hydrochloride Inhibitor 99.42% Phase 2
HY-137432A Avotaciclib trihydrochloride Inhibitor 99.75% Phase 2
HY-103712C Samuraciclib hydrochloride hydrate Inhibitor 99.88% Phase 2
HY-50940A AT7519 TFA Inhibitor 98.53% Phase 2
HY-103712 Samuraciclib Inhibitor / Phase 2
HY-16559A Riviciclib Inhibitor / Phase 2
HY-10008 SNS-032 Inhibitor 99.54% Phase 1
HY-10012 AZD-5438 Inhibitor 99.85% Phase 1
HY-10014 R547 Inhibitor 99.57% Phase 1
HY-12871B Atuveciclib Inhibitor 99.80% Phase 1
HY-11001 PHA-793887 Inhibitor 99.25% Phase 1
HY-15504 RGB-286638 Inhibitor 99.70% Phase 1
HY-12422 Voruciclib Inhibitor 99.77% Phase 1
HY-15504A RGB-286638 free base Inhibitor 98.07% Phase 1
HY-12422A Voruciclib hydrochloride Inhibitor 99.23% Phase 1
Pre-clinical Phase
Bioactive Molecules (89)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-12529 Ro-3306 Inhibitor 99.83% Unkown
HY-12302 Kenpaullone Inhibitor 98.20% Unkown
HY-10329 JNJ-7706621 Inhibitor 99.91% Unkown
HY-124719 hSMG-1 inhibitor 11j Inhibitor 99.82% Unkown
HY-15339 CVT-313 Inhibitor 99.90% Unkown
HY-15154 NG 52 Inhibitor 99.97% Unkown
HY-18340 (R)​-​CR8 Inhibitor 99.61% Unkown
HY-124760 hSMG-1 inhibitor 11e Inhibitor 99.81% Unkown
HY-11009 CGP60474 Inhibitor 99.23% Unkown
HY-N0417 Cucurbitacin E Inhibitor 99.92% Unkown
HY-15275 BMS-265246 Inhibitor 98.92% Unkown
HY-10032 PF 477736 Inhibitor 99.21% Unkown
HY-15878 LDC000067 Inhibitor 99.00% Unkown
HY-18299A Purvalanol A Inhibitor 98.30% Unkown
HY-12445 Asnuciclib Inhibitor 99.76% Unkown
HY-13461A PHA-767491 hydrochloride Inhibitor 99.49% Unkown
HY-18340A (R)-CR8 trihydrochloride Inhibitor 98.95% Unkown
HY-117535 CDK2-IN-4 Inhibitor 96.71% Unkown
HY-13266A BS-181 hydrochloride Inhibitor 99.80% Unkown
HY-18629 SU9516 Inhibitor 99.81% Unkown
HY-12280 THZ2 Inhibitor 99.03% Unkown
HY-X0150 JSH-150 Inhibitor 98.66% Unkown
HY-18299 Purvalanol B Inhibitor ≥97.0% Unkown
HY-119940 MC180295 Inhibitor 98.89% Unkown
HY-129478 TC11 Activator 98.04% Unkown
HY-108359 Alsterpaullone Inhibitor 99.85% Unkown
HY-16559 Riviciclib hydrochloride 98.89% Unkown
HY-15569 NU6102 Inhibitor 99.23% Unkown
HY-15889 AMG 925 Inhibitor 98.20% Unkown
HY-148062 RSS0680 98.03% Unkown
HY-103647 K00546 Inhibitor 98.08% Unkown
HY-107419 NU6140 Inhibitor 99.07% Unkown
HY-103221 MeBIO Inhibitor ≥98.0% Unkown
HY-15241 NVP-LCQ195 Inhibitor 98.81% Unkown
HY-139980 CDK9-IN-13 Inhibitor 99.94% Unkown
HY-19316 NU2058 Inhibitor 99.66% Unkown
HY-112463 CDK1-IN-2 Inhibitor 97.17% Unkown
HY-N5072 Desmethylglycitein Inhibitor 98.98% Unkown
HY-100429 CAN508 Inhibitor 99.59% Unkown
HY-13816 NU6027 Inhibitor 99.04% Unkown
HY-153556 GW297361 Inhibitor 98.13% Unkown
HY-111237 Butyrolactone I Inhibitor 98.03% Unkown
HY-115924 CDK1-IN-1 Inhibitor 99.33% Unkown
HY-112462 Cdk1/2 Inhibitor III Inhibitor 99.69% Unkown
HY-111930 5-Iodo-indirubin-3'-monoxime Inhibitor 99.50% Unkown
HY-103383 (R)-DRF053 dihydrochloride Inhibitor 99.30% Unkown
HY-N12625 (R)-(+)-O-Demethylbuchenavianine Inhibitor 98.67% Unkown
HY-14372 BS-194 Inhibitor 99.36% Unkown
HY-112346 RGB-286147 Inhibitor 98.60% Unkown
HY-103381 NSC693868 Inhibitor ≥99.0% Unkown
HY-136726 CGP-82996 Inhibitor 98.12% Unkown
HY-13266 BS-181 Inhibitor 98.10% Unkown
HY-X0009A JSH-009 dimaleate Inhibitor / Unkown
HY-114903 (E/Z)-BIO-acetoxime Inhibitor / Unkown
HY-15889A AMG 925 (HCl) Inhibitor / Unkown
HY-13461 PHA-767491 Inhibitor 99.85% Unkown
HY-151409 CDK1-IN-5 Inhibitor / Unkown
HY-151407 CDK1-IN-3 Inhibitor / Unkown
HY-126244 CDK4/6-IN-3 Inhibitor / Unkown
HY-163856 CDK7-IN-30 Inhibitor / Unkown
HY-155787 SHR5428 Inhibitor / Unkown
HY-142696 CDK6/PIM1-IN-1 Inhibitor / Unkown
HY-112336 Aloisine RP106 Inhibitor / Unkown
HY-161826 Antitumor agent-174 Inhibitor / Unkown
HY-112363 Aloisine A Inhibitor / Unkown
HY-151071 TMX-3013 Inhibitor / Unkown
HY-146276 CDK/HDAC-IN-2 Inhibitor / Unkown
HY-111931 Indirubin-3'-monoxime-5-sulphonic acid Inhibitor / Unkown
HY-164906 TMX-2138 Degrader / Unkown
HY-168673 CDK1-IN-6 Inhibitor / Unkown
HY-123369 BMI-1026 Inhibitor / Unkown
HY-151408 CDK1-IN-4 Inhibitor / Unkown
HY-151898 CDK4/6-IN-14 Inhibitor / Unkown
HY-151878 CDK7-IN-20 Inhibitor / Unkown
HY-111932 Indirubin-5-sulfonate Inhibitor / Unkown
HY-170306 LZ9 Inhibitor / Unkown
HY-115942 Anticancer agent 29 Inhibitor / Unkown
HY-147901 KDM1/CDK1-IN-1 Inhibitor / Unkown
HY-146253 CDK1/2/4-IN-1 Inhibitor / Unkown
HY-123034 CDKI-83 Inhibitor / Unkown
HY-147646 CDK1/Cyc B-IN-1 Inhibitor 98.47% Unkown
HY-170651 CDK4/6/HDAC-IN-1 Inhibitor / Unkown
HY-141685 3-Methylthienyl-carbonyl-JNJ-7706621 Inhibitor / Unkown
HY-151069 TMX-2039 Inhibitor / Unkown
HY-112450 Olomoucine II Inhibitor / Unkown
HY-112403 (S)-Roscovitine Inhibitor / Unkown
HY-112394 2-Cyanoethylalsterpaullone Inhibitor / Unkown
HY-160643 CDK2-IN-27 Inhibitor / Unkown
HY-123045 PNU-292137 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cdk1 NCBI NCBI:983